| BRCA1/2-Aberrant OC (n = 35) | Wild-Type OC (n = 76) | p-value | ||
---|---|---|---|---|---|
No. | % | No. | % | Â | |
Age at diagnosis, years | Â | Â | Â | Â | Â |
Median | 55 | Â | 64 | Â | <0.001a |
Range | 39–77 |  | 41–82 |  |  |
Histology | Â | Â | Â | Â | Â |
HGS | 34 | 97.1 | 70 | 92.1 | Â |
Endometrioid | 1 | 2.9 | 2 | 2.6 | Â |
Clear Cell | 0 | 0 | 2 | 2.6 | Â |
Mucinous | 0 | 0 | 0 | Â | 0.429b |
LGS | 0 | 0 | 0 | Â | Â |
Carcinosarcoma | 0 | 0 | 2 | 2.6 | Â |
FIGO stage at diagnosis | Â | Â | Â | Â | Â |
I | 1 | 2.9 | 1 | 1.4 | Â |
II | 3 | 8.6 | 4 | 5.6 | Â |
III | 23 | 65.7 | 48 | 66.7 | 0.470c |
IV | 8 | 22.9 | 19 | 26.4 | Â |
NA | 0 | 0 | 4 | Â | Â |
Debulking status | Â | Â | Â | Â | Â |
<2Â cm | 14 | 42.4 | 23 | 31.5 | 0.282e |
≥2 cm | 19 | 57.6 | 50 | 68.5 |  |
NA | 2 | Â | 3 | Â | Â |
Platinum sensitivity at PLD initiation | Â | Â | Â | Â | Â |
Sensitive | 5 | 15.2 | 9 | 12.5 | Â |
Resistant | 28 | 84.8 | 63 | 87.5 | 0.761d |
NA | 2 | Â | 4 | Â | Â |
No. of chemotherapy lines prior to PLD | Â | Â | Â | Â | Â |
≤2 | 25 | 71.4 | 61 | 80.3 | 0.429e |
>2 | 10 | 28.6 | 15 | 19.7 | Â |
Evaluable for PLD response | Â | Â | Â | Â | Â |
Evaluable | 26 | 74.3 | 61 | 80.3 | 0.644e |
Not evaluable | 9 | 15.7 | 15 | 19.7 | Â |